Key facts
- Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio.
- The new site is expected to create about 600 full-time jobs and 1,500 temporary construction jobs.
- Bayer aims to double US sales by the end of the decade.
- Key products supporting the expansion include Kerendia, Nubeqa, and drug candidate asundexian.
- The drug substance manufacturing site is slated to be operational in 2031, with a finished drug product site to follow in 2034.
Bayer's pharmaceuticals division announced on Friday plans for a significant investment of $2.2 billion to establish a new manufacturing facility in New Albany, Ohio. This strategic move is part of the company's broader initiative to increase its revenue generated within the United States.
The new facility is projected to create approximately 600 high-paying jobs, in addition to an estimated 1,500 temporary positions during the construction phase. Sebastian Guth, chief operating officer for pharmaceuticals at Bayer, stated that the decision to strengthen the company's presence in the US is deliberate, complementing its existing strong operations in Europe and Asia.
The expansion is expected to be driven by the performance of key products such as Kerendia for chronic kidney disease, the prostate cancer drug Nubeqa, and the stroke prevention drug candidate asundexian. Bayer aims to double its US sales by the end of the current decade. The company noted that US prescription medicine prices are considerably higher than in other developed nations, a factor that has led President Donald Trump to pressure drugmakers for price reductions.
The drug substance manufacturing site is anticipated to become operational in 2031, with a facility for finished drug products to follow in 2034.